After a median follow-up of 67 months ( IQR 31-90 ) , progression-free survival was longer in the afatinib group than in the methotrexate group ( median 26 months [ 95 % CI 20-27 ] for the afatinib group vs 17 months [ 15-24 ] for the methotrexate group ; hazard ratio [ HR ] 080 [ 95 % CI 065-098 ] , p = 0030 ) .